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Abstract: More than 170 million patients worldwide are chronically infected with hepatitis 
C virus (HCV). Prevalence rates range from 0.5% in Northern European countries to 28% 
in some areas of Egypt. HCV is hepatotropic, and in many countries chronic hepatitis C is 
a leading cause of liver disease including fibrosis, cirrhosis and hepatocellular carcinoma. 
HCV persists in 50–85% of infected patients, and once chronic infection is established, 
spontaneous clearance is rare. HCV is a member of the Flaviviridae family, in which it 
forms its own genus. Many lines of evidence suggest that the HCV life cycle displays 
many differences to that of other Flaviviridae family members. Some of these differences 
may be due to the close interaction of HCV with its host’s lipid and particular triglyceride 
metabolism in the liver, which may explain why the virus can be found in association with 
lipoproteins in serum of infected patients. This review focuses on the molecular events 
underlying the HCV cell entry process and the respective roles of cellular co-factors that 
have been implied in these events. These include, among others, the lipoprotein receptors 
low density lipoprotein receptor and scavenger receptor BI, the tight junction factors 
occludin and claudin-1 as well as the tetraspanin CD81. We discuss the roles of these 
cellular factors in HCV cell entry and how association of HCV with lipoproteins may 
modulate the cell entry process. 
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1. Introduction 
Chronic hepatitis C is a leading cause of chronic hepatitis, cirrhosis, and liver cancer. Worldwide, 
there are currently more than 170 million individuals infected with the hepatitis C virus (HCV), with 
the majority of cases remaining undiagnosed and untreated [1]. The available therapy, a combination 
of pegylated interferon and ribavirin, has limited efficacy and significant side effects; drugs that 
specifically target viral enzymes are yet to reach the market.  
HCV is a small, enveloped virus with a single-stranded RNA genome of positive polarity that 
replicates primarily, if not exclusively, within hepatocytes [2]. Its 9.6-kb RNA genome is translated by 
cellular ribosomes to yield a single polyprotein of approximately 3,000 amino acids, which is cleaved 
by host and viral proteases into the final gene products: core, the glycoproteins E1 and E2, p7, and the 
non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, NS5B, and possibly an alternative 
reading frame protein termed ARFP [2]. Core, E1, and E2 are the structural components of the viral 
particle, whereas the NS gene products NS3 to NS5B mediate genome replication, a process that 
occurs exclusively in the cytoplasm [2]. Progeny virions are thought to bud at intracellular membranes 
and egress via the cellular secretory pathway before going on to infect naïve cells [3]. HCV infection 
alters cellular metabolism, and in particular lipid homeostasis, with important pathological 
consequences [4]. HCV infection has experimentally been shown to augment lipogenesis, and is 
clinically linked to steatosis. These HCV-induced metabolic changes may be important for HCV 
replication and in particular the HCV assembly process, which is closely linked to the hepatic 
triglyceride and VLDL metabolism and may even depend on it [5] (Figure 1). Indirect evidence for a 
link between cellular triglyceride metabolism and HCV assembly is the fact that in patient sera, the 
virus exists in different morphological forms. These forms include more classical virions, which are 
thought to consist of viral capsids containing the viral genome surrounded by a lipid bilayer into which 
the viral envelope glycoprotein complexes are supposed to be incorporated, as well as forms in which 
the virus associates with lipoproteins [6–8]. While only very few information on structural and 
biochemical characterization of lipoprotein-associated virus is available, lipoprotein association has 
profound impact on the viral life cycle of HCV as it is thought to increase the infectious properties of 
the virion and to shield it from immune responses [9,10]. Whether and how HCV-glycoprotein 
mediated cell entry is altered by the association of the virus with lipoproteins is an issue that is being 
actively investigated and that may have important consequences on development of future treatment 
and therapeutics.  
HCV has been reported to transmit frequently by direct exposure to blood products, but the virus 
has also been shown to transmit horizontally [12]. Upon exposure to the virus, it remains unclear how 
the virus transfers from the bloodstream through the liver endothelium into the liver in order to gain 
access to its primary site of replication, the hepatocytes. In contrast, analysis of HCV ‘hepatocyte’ 
entry has made impressive progress over the last few years with the development and availability of  
in vitro HCV infection systems and the identification of the minimal set of required HCV co-receptors.  Viruses 2010, 2                              
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Figure 1. VLDL and HCV assembly. A. VLDL assembly. Upon translation, nascent 
apolipoprotein 100 (apoB100) translocates through the endoplasmatic reticulum (ER) 
membrane. The protein is very unstable and subject to proteasomal degradation, unless it is 
rapidly lipidated. Lipidation of nascent apoB can occur by two different mechanisms. 
Either free MTP binds nascent apoB and subsequently extracts lipids from the membrane 
and transfers them into a hydrophobic pocket of the nascent apoB polypeptide. MTP 
molecules that are not physically associated with apoB can further assist this step and the 
pocket may serve as a nucleation site for lipid deposition. Several rounds of this process 
will result in extensive lipidation of apoB until the apolipoprotein/lipid complex is large 
enough to bud off from the rough ER membrane in the form of an immature VLDL. 
Alternatively, MTP associated with lipid vesicles or droplets may bind to apoB and provide 
a lipid core for the nascent apoB to encircle and wrap around it [11]. It is thought that the 
fusion of immature VLDL with lipidic vesicles derived from smooth ER regions 
(separation of rough and smooth ER membrane regions is indicated in the figure by ][ ) 
induces the maturation and secretion of VLDL from the hepatocytes into the blood.   
B. HCV assembly. HCV core protein localizes to the surface of lipid droplets and is able 
to interact with viral structural proteins assembled on the ER. Furthermore, intracellular 
membranes containing the HCV replication complex are enriched in MTP, apoB, and also 
apoE, and inhibition of the expression or activity of either of these factors blocks the 
release of infectious HCV. Thus, the release of infectious HCV may depend on virions 
being packaged as a VLDL-like particle. 
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Figure 1. Cont. 
 
This review gives a very brief outline of the different forms of infectious virions detected in plasma 
and describes in detail the mechanisms and roles of cellular co-factors in HCV cell entry.  
2. HCV Exists in Lipoprotein-Associated Forms 
Many lines of evidence point to an important role of the very low density lipoprotein (VLDL) 
biosynthesis machinery in the HCV assembly process. Indeed, in patient serum HCV is detected in 
varying forms [7]. Lipoprotein-free or -poor forms of HCV are thought to consist of particles of 50 to 
60 nm diameter surrounded by a lipid bilayer containing the HCV glycoprotein complexes [13]; but 
HCV has also been shown to exist in association with lipoproteins, and this association is thought to 
increase HCV specific infectivity significantly [6,7,9,14,15]. The molecular determinants that lead to 
secretion of HCV that is associated with lipoproteins are not clear, and data on the links between the 
HCV- and the VLDL-assembly machinery remain contradictory. On one hand, it has been reported 
that HCV core protein localizes to the surface of lipid droplets, that virion assembly depends on the 
enzymatic activity of microsomal triglyceride transfer protein (MTP) which lipidates nascent apoB 
lipoprotein [11] and on presence of apoB and apoE [5,16–18] (Figure 1A and B); on the other hand it 
has been shown that HCV-infection inhibits VLDL assembly [19]. Indeed, chronic HCV infection has 
been shown to correlate with hypobetalipoproteinemia, e.g., the retention of VLDL in the liver and 
with steatosis [20]. While the exact links between VLDL and HCV assembly are only starting to be 
explored, it is clear that an association with lipids evokes the partitioning of HCV on density gradients 
into two spectra: particles detected at buoyant densities of ca 1.15 g/mL as well as light, lipoprotein 
containing fractions detected between 1.06 to 1.10 g/mL [6,7,21]. Virions in the light fraction are 
thought to consist of triglyceride-rich lipoproteins containing apoB, apoE and apoC1, viral Viruses 2010, 2                              
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nucleocapsids as well as envelope glycoproteins [6,16,17,21–23]. The fact that HCV particles have 
been shown to contain not only the liver specific apoB100, but also its spliced form apoB48, points to 
the possibility, that HCV may also originate from the intestine [24]. Overall, the morphology of VLDL 
associated HCV particles remains elusive. Importantly, the specific infectivity of HCV produced   
in vitro increases significantly upon passage through a chimpanzee or uPA-SCID mice with human 
liver grafts; and this increase of specific infectivity correlates with an increased portion of lipoprotein-
associated virus [9]. Furthermore, infectivity of lipoprotein-associated virus can be neutralized with 
antibodies targeting several different apolipoproteins, while some antibodies targeted against the viral 
glycoproteins have been shown to demonstrate reduced neutralization efficiency [10,22,25]. Thus, 
lipoprotein-association may favor persistent HCV replication by increasing viral specific infectivity 
and by shielding the virus from humoral immune responses.  
3. HCV Liver Uptake 
In order to establish productive and persistent infection within its primary target, the hepatocytes, 
HCV is thought to need to transfer from the bloodstream through the liver endothelium into the liver at 
very early stages of infection. How uptake of HCV into the liver occurs, and whether lipoprotein 
association can modulate this process remains unclear. The capillary liver endothelium plays a central 
and active role in regulating the exchange of macromolecules, solutes and fluid between the blood and 
liver tissue. Transport across the liver endothelium appears to be a very complex process in which the 
substances are transported according to their size, charge and chemistry. Besides endocytosis and 
transcytosis, endothelial transport in the liver sinusoidal endothelium occurs through fenestrae. Liver 
sinusoidal endothelial cells (LSEC)-fenestrae measure between 100 and 200 nm in diameter, and 
appear to be membrane bound round cytoplasmic holes [26]. Their morphology resembles that of a 
sieve, suggesting their filtration effect [27]. HCV may traverse the liver endothelium by passive 
diffusion through the fenestrae, or by active transcytosis through the liver endothelium. Active 
transcytosis is generally the more favoured hypothesis for three reasons. Firstly, hepatic sinusoidal 
endothelial cells have a remarkable capacity to internalize and process a diverse range of antigens. 
Secondly, in the inflammatory state passive diffusion may be limited due to the expression of different 
classes of adhesion molecules including ICAM-1, VCAM-1, etc., that attract and favour adhesion of 
leukocytes to the liver endothelium. Finally in inflammatory states the fenestrae of the liver 
endothelium tend to ‘close up’ [28]. Indeed, a set of capture receptors called C-type lectins that are 
expressed on liver endothelium and/or dendritic cells have previously been shown to mediate uptake of 
viruses of several different genera, resulting either in transcytosis of the virus across the liver 
endothelial barrier [29–31] or resulting in transfer and transmission of virus to its proper host cells. 
Indeed, DC-SIGN-mediated enhancement of HIV infection is not limited to concentrating viral 
particles onto the cell surface, but involves internalization and complex intracellular trafficking of 
virions [32,33]. DC-SIGN and L-SIGN recognize high-mannose carbohydrates on the surface of 
ligands [34–36] and a large body of evidence suggests that carbohydrate recognition is the sole 
determinant of their ligand specificity  [34–37]. However, while L-SIGN is strictly high-mannose 
carbohydrate specific, DC-SIGN can interact with other carbohydrates. These differences in 
carbohydrate specificity account for differences in the ligand spectrum of these lectins [37,38]. It has Viruses 2010, 2                              
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been shown that both L-SIGN and DC-SIGN can interact with the HCV glycoproteins and capture and 
transmit HCV to adjacent hepatocytes [39–42]. L-SIGN and DC-SIGN are expressed on LSECs and 
dendritic cells, respectively, in vivo, and important questions that remain to be answered are whether, 
by which mechansims and how efficiently these lectins may transfer HCV across the endothelium 
(Figure 2).  
Besides a direct recognition and transfer by C-type lectins, HCV particles may cross the epithelium 
in conjunction with lipoproteins. After secretion from the liver, triglycerides in the cores of 
triglyceride-rich lipoproteins (TRLs) such as VLDL are hydrolyzed by lipoprotein lipase (Lpl), 
resulting in the formation of intermediate-density lipoproteins (IDLs). Lpl can remain associated with 
lipoprotein particles, but most of the enzyme associates with heparan sulfate proteoglycans (HSPG) on 
the surface of endothelial cells [43,44]. The mechanism of hepatic clearance of TRLs remains 
controversial. The particles may diffuse through fenestrae or are transcytosed through the endothelium 
and then sequester in the liver perisinusoidal space (space of Disse), where they undergo further 
processing by hepatic lipase (HL) and Lpl, both of which are detectable in the space of Disse and may 
remain associated with TRLs [45,46]. Lipoprotein lipase and hepatic lipase may furthermore have 
additional functions by serving as bridging factors for receptor-mediated lipoprotein uptake. However, 
lipoprotein lipase mediated uptake of HCV has recently been shown to result in non-productive 
infection [47]. On the hepatocytes surface, multiple receptors mediating clearance of TRL remnants 
and their lysosomal catabolism appear to exist. These include the low density lipoprotein receptor 
(LDLr), the LDLR-related protein (LRP), scavenger receptors (SR) and cell-surface HSPGs [48].  
Besides sinusoidal endothelial cells, two additional non parenchymal liver-resident cell types, line 
the walls of hepatic sinusoids: Kupffer cells and hepatic stellate cells (Figure 2). In addition, 
intrahepatic lymphocytes are often present in the sinusoidal lumen. The role of these different cell 
types in liver and cell entry of canonical or lipoprotein-associated HCV has so far not been 
investigated. Interestingly, one report suggests that B cells may serve as a means for HCV to cross the 
liver endothelial barrier. Indeed, cell culture produced HCV has been shown to associate and to be 
endocytosed by B cells and B cell–associated virus readily transmits to and infects hepatoma cells, 
showing an enhanced infectivity compared with extracellular virus [49]. 
4. Hepatocyte Uptake of HCV Particles 
The infection process begins with the attachment of a virus to the surface of its host cell and is 
usually mediated by an envelope glycoprotein complex that is anchored into the surface of the viral 
particle. With the availability of the first HCV in vitro infection systems [13,50–54], it has become 
clear at least in the context of HCV particles of canonical density, which are lipoprotein-free or -poor, 
that the HCV glycoproteins are required for the cell entry process and mediate cell attachment, virion 
internalization and fusion [13,50]. Whether this holds true for lipoprotein-associated or   
-enriched forms of HCV, is currently being investigated. Two HCV in vitro infection systems are 
predominantly used to study HCV cell entry. The first system, HCV pseudoparticles (HCVpp), 
consists of retroviral core particles surrounded by a lipid bilayer containing functional HCV E1E2 
complexes [50–52]. Into the retroviral core, a retroviral genome encoding marker genes for 
fluorescent, luminescent or selective detection can be incorporated [55]. The most prominent features Viruses 2010, 2                              
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of HCVpp are that they can be engineered to display the HCV glycoproteins of any viral genotype and 
that they mediate an abortive infection cycle and allow the integration of various marker genes. The 
second system consists of replicative HCV particles termed HCVcc, which are produced from a 
particular HCV genome, isolated from a fulminant Japanese hepatitis case. This viral isolate is the only 
one known to replicate productively in vitro [13,53,54]. With the development of this system, study of 
the complete HCV life cycle has finally become possible. 
Like for many other viruses, glycosaminoglycans seem to be an initial docking site for HCV 
attachment [56,57]. After the initial attachment to its host cell, a virus generally binds to specific 
cellular entry factors, which are responsible for initiating a series of events that eventually lead to the 
release of the viral genome into the cytosol. A number of cellular factors have been shown to be 
required for the HCV cell entry process, but their exact roles remain unclear. These comprise the 
tetraspanin CD81, the lipoprotein receptor scavenger receptor BI (SR-BI) as well as two tight junction 
factors called claudin 1 (CLDN) and occluding (OCLN).  
4.1. The Tetraspanin CD81 
The first HCV entry factor shown to be required for HCV cell entry was the tetraspanin CD81 [58]. 
CD81 is a member of the tetraspanin superfamily and very ubiquitiously expressed. Key feature of 
tetraspanins is the formation of an extended network at the cell surface, which is thought to structure 
the membrane by coordinating homologous, autologous and heterologous protein interactions. Such 
'tetraspanin-enriched microdomains' (TEMs) are emerging to play important roles in cellular 
signalling, cytoskeletal reorganization, migration, adhesion, fusion and proliferation; but very recently 
the association of CD81 with TEMs has been shown not to be required for HCV cell entry [59]. 
Tetraspanins have overall no intrinsic enzymatic activity and are rather thought to function as adaptor 
proteins by sorting and modulating localization and interactions of membrane resident proteins. 
Infection of primary human hepatocytes or hepatoma cell lines was inhibited by anti CD81 antibodies 
[13,51,53,60,61] and after downregulation of CD81 using an siRNA approach [62]. HepG2 and HH29 
cells, hepatoma cell lines, which do not express endogenously CD81, become permissive to HCVpp of 
all genotypes upon ectopic CD81 expression [60,62,63]. These data were confirmed with HCVcc 
[13,53]. At which step of the HCV cell entry process CD81 is involved remains unclear. Solubilized 
E2 protein can bind to CD81 and a recombinant expressed form of the large extracellular loop of CD81 
can bind to HCV [58], suggesting that CD81 may be a binding factor. However, several laboratories 
have shown that in receptor competition assays, anti-CD81 antibodies can inhibit infection to similar 
extents whether added before, with or after virus-cell incubation, suggesting that either the primary 
role of CD81 is not to mediate binding of the virus to the cell surface [64,65], or that the role of CD81 
extends beyond. Interestingly, a protein found to interact with CD81, which is expressed ubiquitiously 
but not in hepatocytes, has been found to inhibit HCV-CD81 interactions and to block HCV cell entry 
in a dominant-negative fashion [66]. Furthermore, HCV has been shown to spread by cell-to-cell 
transmission, a process that can occur independently of CD81 [67,68]. The importance of direct cell-
to-cell transmission of HCV in vivo, within the infected liver, remains to be evaluated. Viruses 2010, 2                              
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Figure 2. HCV liver and cell entry. HCV circulates in the blood in canonical and 
lipoprotein-associated forms. To cross from the fenestrated sinusoidal liver endothelium 
into the space of Disse, HCV may diffuse through fenestrae or it may be captured and 
transcytosed by C-type lectins L-SIGN or DC-SIGN, expressed on the liver endothelium 
and dentritic cells, respectively. Alternatively, heparan sulfate proteoglycans (HSPG) on 
the surface of endothelial cells may favor the transfer of canonical and lipoprotein-
associated virus into the liver. In the liver, canonical HCV hepatocytes entry requires the 
cellular entry factors scavenger receptor BI (SR-BI), the tetraspanin CD81 as well as 
Occludin and Claudin-1, tight junction factors that play a role in the physical separation of 
basolateral and apical membranes. HSPG and low density lipoprotein receptor (LDLr) have 
also been implied in HCV cell entry, but whether their roles apply particularly to 
lipoprotein-associated HCV remains unclear. HCV-virions are internalized into 
hepatocytes by clathrin-mediated endocytosis and overall the roles of the various HCV 
entry factors in cell attachment, internalization and fusion are not yet elucidated. Please 
refer to the text for further details. 
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4.2. The Scavenger Receptor BI 
The scavenger receptor class B type I (SR-BI), also called CLA-1, functions as lipoprotein receptor 
that mediates selective uptake of cholesteryl ester from apoA containing lipoproteins and in particular 
high density lipoprotein (HDL), via a two-step mechanism involving the binding of lipoproteins to its 
extracellular domain followed by lipid uptake [69]. SR-BI was identified as co-receptor for HCV cell 
entry in binding assays with a soluble form of E2 glycoprotein (sE2) [70]. SR-BI recognition by sE2 
required the hyper variable region 1 of E2 (HVR1) and antibodies against SR-BI were shown to inhibit 
HCV infection [60], suggesting an important role for SR-BI in HCV cell entry. Interestingly, kinetics 
of inhibition with anti-SR-BI and anti-CD81 antibodies suggest that SR-BI might act concomitantly 
with CD81 [64], but the fact that HCVcc bind SR-BI expressing CHO cells but not CD81 expressing 
CHO cells [71] may imply that a first contact with SR-BI is necessary before the viral particle can 
interact with CD81. An important role for SR-BI in HCV entry was confirmed by observations that 
specific ligands to SR-BI such as high density lipoprotein (HDL) and oxidized low density lipoprotein 
modulate the infectivity of HCV [72–74]. With the establishment of functional complementation 
assays it has now become clear that SR-BI and its physiological lipid transfer activity are required for 
HCV cell entry [75,76]. Mutational analysis of SR-BI in receptor complementation assays has shown 
that the intracellular C-terminal cytoplasmic tail of SR-BI modulates HCV infection. A C-terminal 
deletion mutant, expression of the spliced form SR-BII which displays an alternative C-terminal tail or 
the replacement of the SR-BI cytoplasmic tail in an SR-BI/CD36 chimera all reduced HCV infection. 
These data suggest that the C-terminal tail of SR-BI does influence the HCV cell entry process. 
Whether the C-terminal tail modulates intracellular trafficking, membrane localization or other 
mechanisms remains to be seen. Interestingly, interference with the interaction of SR-BI with PDZK1, 
an enzyme that regulates localization, assembly and scaffolding of SR-BI [77], by mutation of the 
AKL motif in the C-terminus of SR-BI, did not affect HCV entry. Mutational analysis of SR-BI in 
receptor competition assays showed that the lipid transfer properties of SR-BI are required for HCV 
cell entry. SR-BI takes up cholesterol ester (CE) from low and high density lipoproteins via a two-step 
mechanism. In the case of HDL, it has been shown that SR-BI binds HDL with high-affinity and 
mediates lipid uptake by transferring the lipids to the cholesterol pool of the target cell membrane 
[69,78]. 
4.3. The Tight Junction Factors Claudin-1 and Occludin 
Besides SR-BI and CD81, two additional factors that are essential for HCV cell entry - probably at 
late stages - have been identified by expression cloning. These are claudin-1 (CLDN1) and occludin 
(OCLN) [71,76]. In addition, Claudin-6 and -9 have been shown to enable HCV entry into 
nonpermissive cells in replacement of Claudin-1 [79]. CLDN1 and OCLN are two factors that are 
expressed at the interface between basolateral and apical membranes. At this location, they form part 
of tight-junctions that regulate paracellular transport of solutes, water and ions and separate the space 
of Disse from the bile canaliculi thus generating apical-basal cell polarity (see Figure 2). With the 
discovery of TJ proteins as entry factors, the role of cell differentiation and polarization in the HCV 
cell entry process have become important issues. On the one hand the dependence of HCV assembly Viruses 2010, 2                              
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on an active VLDL assembly machinery suggests indirectly that cell differentiation is important for 
HCV production, because VLDL assembly is a metabolic function that characterizes differentiated 
hepatocytes. On the other hand, HCV infection has been shown to provoke the downregulation of 
CLDN1 and OCLN expression and TJ function and to induce depolarization of infected hepatocytes 
with potential pathological consequences [80,81]. The negative effect of HCV infection on OCLN 
expression has been shown to be due to the induction of vascular endothelial growth factor [82]. 
In addition, the roles of CLDN1 and OCLN in HCV cell entry imply that parallels between HCV 
and coxsackievirus B (CVB) cell entry may exist. CVB interacts with its primary receptor decay 
accelerating factor, and this interaction induces lateral movement of the virus-receptor complex 
towards TJs, where the binding of the virus to coxsackie-adenovirus receptor triggers virus 
internalization [83]. In a similar fashion, an interesting set of data suggests that upon engagement with 
HCV, CD81 triggers intracellular signaling responses that lead to actin remodeling and relocalization 
of CD81 away from the basolateral membrane towards TJs [84]. Thus CD81 may function as a shuttle 
to transfer the virus from the basolateral surface towards TJs. The actual roles of CLDN1 and OCLN 
in HCV cell entry remain unclear, but interestingly a direct interaction between the HCV envelope 
glycoproteins and OCLN has been shown [85]. Furthermore, knock-down of OCLN in a cell-cell 
fusion assay, where fusion activity depends on cell surface expression of the HCV glycoprotein 
complex, diminished fusion activity, suggesting that OCLN may be implied in the HCV fusion process 
[86]. Receptor complementation with deleted or mutated versions of CLDN1 demonstrated that the 
extracellular loop 1 of claudin-1 [71] and more particularly a highly conserved motif required for cell-
cell contact formation is required for HCV entry [87]. Finally, downregulation of other TJ factors such 
as junctional adhesion molecule A or zonula occludens protein 1 did not affect HCV cell entry [86].  
4.4. The Route of HCV Cell Entry 
The uptake of HCV into hepatocytes has been shown to be dependent on clathrin-mediated 
endocytosis [88], and experimental evidence based on drugs that inhibit acidification of endosomes 
have furthermore shown that low pH in endosomes is required for the HCV cell entry process [60,89]. 
With the set up of in vitro fusion assays, based on liposomes that do not display any cellular factors, it 
was furthermore shown that HCV fuses with liposomes in a low pH-dependent manner [90]. 
Curiously, low pH exposure of HCV virions does not inactivate the function of the glycoprotein 
complex in cell entry and fusion, suggesting that besides low pH exposure additional triggers or 
modifications are required to activate the fusion machinery of the HCV glycoprotein complexes [89]. 
HCV internalization before and after the uncoating process has furthermore been shown to depend on 
intact microtubules and their dynamic turnover [91]. 
5. Contribution of VLDL to Hepatocyte Uptake of HCV 
Besides CD81, SR-BI, CLDN and OCLN, a potential involvement of the low density lipoprotein 
receptor (LDLr) in HCV cell entry has been reported by many groups. The potential involvement of 
LDLr in HCV entry originated with the observation that HCV infection is associated with mixed 
cryoglobulinemia, where VLDL is selectively associated with HCV in type II cryoglobulin complexes 
[92]. This observation, together with the finding that anti-apoB is associated with HCV in infected Viruses 2010, 2                              
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serum, suggested that LDLr may be a receptor for HCV complexed to VLDL or LDL [8,10,16,23,93]. 
While in the cell entry process of lipoprotein-free or -poor HCV, so far not much evidence has pointed 
to a role for the LDLr, this scenario has started to change dramatically with the availability of in vitro 
produced authentic HCV particles that can be recovered in light, lipoprotein containing fractions of 
density gradients. Indeed, it has been shown that endocytosis of HCV correlates with the presence of 
LDLr and its activity by performing receptor competition assays with anti LDLr antibodies, with anti-
apoB and apoE antibodies as well as with VLDL and LDL [10,16,18,23,27,93]. Furthermore, knock 
down of LDLr in primary hepatocytes has been shown to interfere with HCV infection [61]. The 
physiological role of the LDLr is to transport cholesterol-containing lipoprotein particles from the 
extracellular medium into cells. The most important physiological ligand for the LDLr is the apoB100 
containing low density lipoprotein (LDL). In addition, the receptor also exhibits high-affinity binding 
of lipoproteins that contain multiple copies of apoE, like some forms of VLDL and certain 
intermediate density lipoproteins. Receptor ligand complexes enter cells by endocytosis via clathrin-
coated pits and are delivered to endosomes, where low pH triggers release of bound lipoprotein 
particles. Released lipoprotein particles proceed to lysosomes, where the cholesterol esters are 
hydrolyzed to free cholesterol [94].  
Thus interactions between apoB or apoE associated with HCV and the LDLr may be involved in 
liver uptake as well as initial attachment to the hepatocyte cell surface. These processes may be further 
modified by Lpl, which has been shown to be involved in HCV cell entry, albeit in a non-productive 
fashion [47]. Non-specific cell attachment may favor subsequent interaction of the HCV glycoproteins 
with CD81, trafficking of this complex towards TJs, followed by internalization and fusion. To what 
extent lipoprotein-association and lipidation status of the lipoprotein/virus complex alters or modifies 
the requirement for the HCV co-receptors or modulates their respective roles, remains to be seen.  
6. Conclusions 
The association of HCV with lipoproteins is thought to serve as a mechanism to increase infection 
and to escape immune detection and help the virus to maintain persistent infection over time. It may 
also help, at least in part, to explain the hepatotropism of HCV. Indeed, apolipoproteins regulate the 
uptake of lipid particles to the liver. At the same time does the association of HCV with lipoproteins 
pose technical challenges and limitations to the research field. Biochemical isolation and 
characterization of lipoprotein associated virus is proving difficult and production efficiency of HCV 
and HCV lipoprotein-association vary furthermore with cell culture conditions. Thus comparative 
analysis of in vitro produced forms of HCV is an important but difficult task. The use of HCV derived 
from patient sera in in vitro infection systems is notoriously difficult due to the genetic and 
morphological heterogeneity of HCV, which may in part be determined by the metabolic 
predisposition of its host. But with novel cell culture systems that support survival of differentiated, 
polarized hepatocytes cultures, which are metabolically active for prolonged periods of time, studying 
the importance of the liver lipid metabolism in the HCV life cycle and particularly the cell entry 
process may become more feasible.  
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